Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

BACKGROUND: The Ad26.COV2.S vaccine was highly effective against severe–critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy analysis. METHODS: We conducted the final analysis in the double-blind phase of our multinational, randomized, placebo-cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadoff, Jerald, Gray, Glenda, Vandebosch, An, Cárdenas, Vicky, Shukarev, Georgi, Grinsztejn, Beatriz, Goepfert, Paul A., Truyers, Carla, Van Dromme, Ilse, Spiessens, Bart, Vingerhoets, Johan, Custers, Jerome, Scheper, Gert, Robb, Merlin L., Treanor, John, Ryser, Martin F., Barouch, Dan H., Swann, Edith, Marovich, Mary A., Neuzil, Kathleen M., Corey, Lawrence, Stoddard, Jeffrey, Hardt, Karin, Ruiz-Guiñazú, Javier, Le Gars, Mathieu, Schuitemaker, Hanneke, Van Hoof, Johan, Struyf, Frank, Douoguih, Macaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849184/
https://www.ncbi.nlm.nih.gov/pubmed/35139271
http://dx.doi.org/10.1056/NEJMoa2117608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849184/
https://www.ncbi.nlm.nih.gov/pubmed/35139271
http://dx.doi.org/10.1056/NEJMoa2117608

Ejemplares similares